

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

In The Name Of ALLAH

The Most Gracious, The Most Merciful



# **Armed Forces College of Medicine AFCM**

**Endocrine & Urogenital  
Module**



# **Male & Female Sex Hormones**

## **Analogs & Inhibitors 1**

**Prof. / Omayma Khorshid**


# INTENDED LEARNING OBJECTIVES (ILO)



- 1.
- 2.
- 3.
- 4.


# **Anti-androgens**

# Anti-androgens



cytoplasm

Nucleus



a

Testosterone

Androgen  
receptor


DHT

5 $\alpha$ -reductase

Transcription

Cytoplasm

Nucleus






# Finasteride (5 $\alpha$ -reductase inhibitor)

- **a steroid-like inhibitor of 5 $\alpha$  reductase  $\rightarrow$   $\downarrow$  conversion of testosterone to dihydrotestosterone**

*N.B: Some tissues, most notably: prostate cells and hair follicles depend on DHT Rather than testosterone for androgenic stimulation.*

- **Used for:**  
**1-benign prostatic hyperplasia**  
**2- hirsutism in females**  
**(lower dose)**


*Because the drug does not interfere with the action of antiandrogens to cause impotence, infertility, and*



# **Androgen Receptors Antagonist Flutamide**

- **a nonsteroidal antiandrogen that acts like a competitive antagonist at androgen receptors**
- **Used in:**
  - Prostatic Ca**
  - Hirsutism in females (also spironolactone )**


# **Female Sex Hormones**




# Preparations of Estrogens



# Synthesis



# Mechanism of Action of estrogen



**Figure 26.2**

Transcriptional regulation by intracellular steroid hormone receptors. ERE = estrogen response element; ER = estrogen receptor.

# Mechanism of Action

- Steroid hormones diffuse across the cell membrane and bind with high affinity **to specific nuclear-receptor proteins.**
- The activated **steroid-receptor complex interacts with nuclear chromatin** to **initiate hormone-specific RNA synthesis.**
- This results in the **synthesis of specific proteins** that mediate a number of physiologic functions.



# Mechanism of Action

**Other pathways have been identified lead to more rapid actions:**

- For example, activation of an estrogen receptor in the membranes of hypothalamic cells has been shown to couple to a G protein, thereby initiating a second-messenger cascade.
- In addition, estrogen-mediated dilation of coronary arteries occurs by the increased formation and release of nitric oxide and prostacyclin in endothelial cells.

# Classification of Preparations

## 1. Natural estrogens: Contain a *steroid nucleus*

### Estradiol

- is the most potent and the principal estrogen secreted by the ovary.
  - metabolized In the liver: to less potent metabolites
  - **orally have low bioavailability??? undergo first- pass metabolism**
- 

## 2. Synthetic oestrogens: Orally

Have prolonged action (stored in fat) & higher potency

- Ethinyl estradiol:  
Highly potent, taken orally (ethinyl group protects from inactivation).
- Mestranol: rapidly demethylated to **Ethinyl Estradiol**.
- Estradiol valerate:
  - cleaved to estradiol and valeric acid
  - Also available as parenteral dosage form (I.M)

- Most estrogens are absorbed from skin and mucous membrane and can be given as transdermal patches.
- Can be given topically in the vagina as pessaries or creams for local effect but some of the drugs can be absorbed.

# Pharmacological Actions

## 1) Uterus:

Responsible for the **proliferative phase** of the cycle on endometrium.  
Together **with progesterone for the "secretory phase"**.  
Estrogens affect the growth of the myometrium & ↑ sensitivity to oxytocin.

## 2) Breast:

stimulates growth of the mammary glands (the duct system and nipple).

## 3) Alterations in composition of plasma lipids:

↓ LDL.

↓ Plasma cholesterol.

↑ HDL

↑ Plasma triglycerides.

#### **4) ↑ ↑ deposition of Ca++ in bones,**

rapid growth of long bones during puberty in females  
and acceleration of epiphyseal closure.

#### **5) Blood Coagulation:**

estrogens **enhance** the coagulability of blood.

↑ circulating levels of factors II, VII, IX and X (2,7,9 & 10)

**High incidence of thromboembolic disease**

# Therapeutic uses

**1) Contraception:** with progestogens.

**2) Postmenopausal hormonal therapy (HT)**  
**for menopausal symptoms” hot flushes & vaginal atrophy”.**

- With intact uterus add progestogen to # risk of endometrial carcinoma.
- Doses of HT are less than that in oral contraception → less side effects
- Lowest effective doses for the shortest possible time (for risk of side effect)
- If only vaginal atrophy → use vaginal estrogen

**3) Replacement therapy (estrogen & progestogen) in:**

- 1ry hypogonadism (ovarian failure).
- Premature menopause
- Surgical menopause

# Adverse effects

- 1) Nausea and Breast tenderness (most common)
- 2) Thromboembolic events & myocardial infarction**  
(contraindicated with history of **Thromboembolism**)
- 3) Salt & water retention → **edema & hypertension** →  
**↑ ↑ weight gain**
- 4) Increased blood sugar levels
- 5) Risk of **breast cancer**.
- 6) Risk of endometrial carcinoma** # by progesterone.
- 7) Carcinoma of vagina** in women whose mother was  
treated **by estrogen early in pregnancy**

## SUGGESTED TEXTBOOKS



1.

2. Katzung BG, Trevor AJ. (2018). Basic & Clinical Pharmacology (14<sup>th</sup> edition) New York: McGraw-Hill Medical.





**THANK  
YOU**